Furthermore, Schedule III could mean that independent researchers—not just pharma shills—might finally get a seat at the table. Universities won’t have to fear losing their funding just for touching the plant. We might see a new wave of “less biased” research that explores the nuances of the entourage effect or minor cannabinoids like THCV or CBG, rather than just focusing on how much “reefer madness” can be induced in a lab rat.
Legal on paper, restricted in practice. Inside Germany’s cannabis system, where cultivation is allowed but…
The idea may sound strange: a tobacco plant producing compounds like psilocybin or DMT. Sounds…
The term “addiction” gets thrown around quite freely in everyday language—this is nothing new. Who…
Three days before the Trump administration moved medical marijuana to Schedule III, a new YouGov…
On April 23, 2026, the Trump administration officially moved FDA-approved marijuana products and marijuana products…
Here we are in 2026, and a conflict that was supposed to wrap up in…